Shiohira Hideo, Nakamatsu Masashi, Kise Yuya, Higa Futoshi, Tateyama Masao, Hokama Nobuo, Kuniyoshi Yukio, Ueda Shinichiro, Nakamura Katsunori, Fujita Jiro
Department of Hospital Pharmacy, Faculty of Medicine, University of the Ryukyus.
Yakugaku Zasshi. 2016;136(9):1313-7. doi: 10.1248/yakushi.15-00296.
Teicoplanin, a glycopeptide antibiotic for methicillin-resistant Staphylococcus aureus, is recommended for therapeutic drug monitoring during treatment. Maintaining a high trough range of teicoplanin is also recommended for severe infectious disease. However, the optimal dose and interval of treatment for severe renal impairment is unknown. We report a 79-year-old man who received long-term teicoplanin treatment for methicillin-resistant Staphylococcus aureus bacteremia due to postoperative sternal osteomyelitis with renal impairment. Plasma teicoplanin trough levels were maintained at a high range (20-30 μg/mL). Although the patient required long-term teicoplanin treatment, a further decline in renal function was not observed, and blood culture remained negative after the start of treatment. Teicoplanin treatment that is maintained at a high trough level by therapeutic drug monitoring might be beneficial for severe methicillin-resistant Staphylococcus aureus infection accompanied by renal impairment.